secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2024-12-27T23:59:59+00:00
Accession:  0001104659-24-131957
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics reports FY2024 net loss of $75.4M; LYTENAVA launch plans for H1 2025
--------------------------------------------------------------------------------

- Net loss of $75.4M ($4.06 per share) vs $59.0M ($4.72 per share) in prior fiscal year.
- Cash and cash equivalents of $14.9M as of September 30, 2024.
- LYTENAVA (bevacizumab gamma) approved in EU and UK for wet AMD; NICE recommends in UK.
- NORSE EIGHT month 3 efficacy data expected January 2025; BLA resubmission targeted Q1 2025.
- First commercial launches in UK and Germany planned H1 2025; potential US FDA approval H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924131957/0001104659-24-131957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924131957/tm2431904d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-131957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer